Literature DB >> 7919347

Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia.

M Taniwaki1, K Nishida, T Takashima, H Nakagawa, H Fujii, T Tamaki, C Shimazaki, S Horiike, S Misawa, T Abe.   

Abstract

Structural chromosomal abnormalities and their break-points were characterized in 17 patients with multiple myeloma (MM) and 4 with plasma cell leukemia by banding. Chromosome 14q32 translocations with a variety of partners were detected in 13 patients, and a variant translocation t(8;22)(q24.1;q11) was detected in 1. Three recurrent 14q32 translocations have been identified: t(6;14)(p21.1;q32.3) occurring in 3 cases, and t(11;14)(q13;q32.3) and t(14;18) (q32.3;q21.3) each occurring in 2 cases. Translocations t(1;14)(q21;q32.3), t(3;14)(p11;q32),t(7;14)(q11.2;q32.3), and t(11;14)(q23;q32.3) were found in each patient, whereas in the remaining 2 patients, partner chromosomes could not be determined. The band 19p13.3 was newly delineated as a recurrent breakpoint involved in translocations in MM. Chromosomes 1 and 6 were also commonly involved in structural abnormalities (14 and 10 patients, respectively), although no particular bands were noted. However, the short arm of chromosome 1 was preferentially involved in deletion, suggesting a certain antioncogene on 1p associated with the development of myeloma. In addition; fluorescence in situ hybridization was successfully applied to determine the nature of the structural abnormalities in a patient with t(8;22) translocation. The present findings suggest that there may be subsets of 14q32 translocations specific to MM.

Entities:  

Mesh:

Year:  1994        PMID: 7919347

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

2.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

Authors:  Ichiro Hanamura; James P Stewart; Yongsheng Huang; Fenghuang Zhan; Madhumita Santra; Jeffrey R Sawyer; Klaus Hollmig; Maurizio Zangarri; Mauricio Pineda-Roman; Frits van Rhee; Federica Cavallo; Bart Burington; John Crowley; Guido Tricot; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-16       Impact factor: 22.113

3.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Authors:  P L Bergsagel; M Chesi; E Nardini; L A Brents; S L Kirby; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

4.  The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.

Authors:  Kathleen E Lambert; Huang Huang; Karthikeyan Mythreye; Gerard C Blobe
Journal:  Mol Biol Cell       Date:  2011-03-16       Impact factor: 4.138

5.  Variant Burkitt-type translocation (8;22)(q24;q11) in plasma cell myeloma.

Authors:  Hanah Kim; Hee-Won Moon; Mina Hur; Yeo-Min Yun; Chul-Min Park; Mark Hong Lee
Journal:  Korean J Hematol       Date:  2011-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.